Relapsing Remitting Multiple Sclerosis: Clinical Trials

15 trials for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed. 15 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 215Completed 15
Phase 31Completed 1

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
PIPE-307 Dose A, PIPE-307 Dose B, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedJanssen Research & Development, LLC1822023-11-062026-09-25
An Extension of the TG1101-RMS201 Trial
Ublituximab - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedTG Therapeutics, Inc.482017-06-012022-12-21
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
IL2, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedAssistance Publique - Hôpitaux de Paris302016-06-132020-11-09
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
RHB-104 - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedRedHill Biopharma Limited182013-06-012016-07-28
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
Raltegravir - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedQueen Mary University of London232013-04-012017-05-30
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
Boswellic acids (BOSWELAN) - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedUniversitätsklinikum Hamburg-Eppendorf292011-09-012020-02-25
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
NT-KO-003 - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedNeurotec Pharma992011-06-012014-03-18
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
BAF312 - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedNovartis Pharmaceuticals1852010-08-302018-03-27
Treatment Interruption of Natalizumab
natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedBiogen1752010-03-012013-09-19
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
Estriol, Placebo, Copaxone - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedUniversity of California, Los Angeles1582007-03-012016-06-16
A Study for Patients With Relapsing Remitting Multiple Sclerosis
dirucotide, placebo - Relapsing Remitting Multiple Sclerosis
Phase 2 / Phase 3CompletedEli Lilly and Company2182006-11-012010-09-09
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
BHT-3009 0.5 mg, BHT-3009 1.5 mg, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedBayhill Therapeutics2522006-02-012008-02-11
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
laquinimod 0.3, laquinimod 0.6, Placebo - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.3062005-03-012011-04-08
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
interferon beta treatment to add-on atorvastatin treatment, untreated to atorvastatin treatment - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedCharite University, Berlin, Germany412003-10-012018-03-20
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
glatiramer acetate 20 mg, glatiramer acetate 20 mg, with mitoxantrone - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.402003-06-012011-04-14

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (15)  ·  Multiple Sclerosis (4)  ·  Autoimmune Diseases (1)

Broader conditions

Autoimmune Diseases of the Nervous System (15)  ·  Demyelinating Autoimmune Diseases, CNS (15)  ·  Demyelinating Diseases (15)  ·  Immune System Diseases (15)  ·  Nervous System Diseases (15)  ·  Autoimmune Diseases (14)  ·  Multiple Sclerosis (11)

Interventions

Glatiramer Acetate (3)  ·  BHT 3009 (1)  ·  Estriol (1)  ·  Estrogens (1)  ·  Interferon beta-1a (1)  ·  Interleukin-2 (1)  ·  MBP-8298 (1)  ·  Methylprednisolone (1)  ·  Mitoxantrone (1)  ·  Natalizumab (1)  ·  Raltegravir Potassium (1)  ·  Sugars (1)  ·  siponimod (1)  ·  ublituximab (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Bayhill Therapeutics (1)  ·  Biogen (1)  ·  Charite University, Berlin, Germany (1)  ·  Eli Lilly and Company (1)  ·  Janssen Research & Development, LLC (1)  ·  Neurotec Pharma (1)  ·  Novartis Pharmaceuticals (1)  ·  Queen Mary University of London (1)  ·  RedHill Biopharma Limited (1)  ·  TG Therapeutics, Inc. (1)  ·  University of California, Los Angeles (1)  ·  Universitätsklinikum Hamburg-Eppendorf (1)

Countries

United States (5)  ·  Germany (4)  ·  Spain (3)  ·  Canada (2)  ·  Poland (2)  ·  Russia (2)  ·  Bulgaria (1)  ·  Finland (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Norway (1)  ·  Serbia (1)  ·  Slovakia (1)

Top investigators

Anne Cross, M.D. (1)  ·  Anthony Reder, M.D. (1)  ·  Barbara Giesser, M.D. (1)  ·  Christoph Heesen, MD (1)  ·  Corey Ford, M.D. (1)  ·  David Klatzmann (1)  ·  Dean Wingerchuk, M.D. (1)  ·  Dina Jacobs, M.D. (1)  ·  Elliot Frohman, M.D. (1)  ·  Frank Valone, MD (1)  ·  Frauke Zipp, MD (1)  ·  Gareth Parry, M.D. (1)  ·  Gavin Giovannoni (1)  ·  Ira N Kalfus, MD (1)

Results publications

PMID 18398457, PMID 18572078, PMID 26049148, PMID 26621682, PMID 27380540, PMID 30873106, PMID 37245191, PMID 38648580

NIH funding

2004 (1), 2009 (1), 2014 (1), R01NS051591 (1)